ReviewPharmaceuticals (Basel, Switzerland)2021

Reversing an Oncogenic Epithelial-to-Mesenchymal Transition Program in Breast Cancer Reveals Actionable Immune Suppressive Pathways.

Michelle M Williams et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.